AAV介导的听力损失基因治疗进展

doi:10.3969/j.issn.0253-9608.2021.01.006

摘要/Abstract

摘要： 听力损失是常见的感觉障碍之一，尚没有非设备手段可以恢复听力。近年来听力疾病的基因疗法正在走向科研研究前端并逐步迈向临床。腺相关病毒（AAV）是目前最常用的基因治疗载体，在听力疾病的基因治疗中发挥重要作用。文章简要综述了天然AAV的结构与分型，以Anc80L65、AAV2.7m8、AAV-ie为例阐述AAV介导的听力损失基因治疗的可能性，并展望其未来的进展。

关键词: , AAV；听力损失；基因治疗

Abstract: Hearing loss is one of the common sensory disorders, and there is no non-device means to restore hearing. In recent years, gene therapy for hearing diseases has gradually moved to the forefront of scientific research and clinical practice. Adeno-associated virus（AAV）is the most commonly used gene therapy vector and plays an important role in the gene therapy of hearing diseases. In this paper, the structure and type of natural AAV were briefly reviewed, and the possibility of AAV-mediated gene therapy for hearing loss was discussed with Anc80L65, AAV2.7m8 and AAV-ie as examples, and the future progress of AAV-mediated gene therapy for hearing loss was also discussed.

柯君子, 谈方志, 钟桂生. AAV介导的听力损失基因治疗进展 [J]. 自然杂志, 2021, 43(1): 39-44.

KE Junzi, TAN Fangzhi, ZHONG Guisheng. Advances in AAV-mediated gene therapy for hearing loss [J]. Chinese Journal of Nature, 2021, 43(1): 39-44.

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: https://www.nature.shu.edu.cn/CN/10.3969/j.issn.0253-9608.2021.01.006

https://www.nature.shu.edu.cn/CN/Y2021/V43/I1/39

[1] GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017 [J]. Lancet, 2018, 392(10159): 1789-1858.

[2] WILSON B S, TUCCI D L, MERSON M H, et al. Global hearing health care: new findings and perspectives [J]. Lancet, 2017, 390(10111): 2503-2515.

[3] LESICA N A. Why do hearing aids fail to restore normal auditory perception? [J]. Trends Neurosci, 2018, 41(4): 174-185.

[4] CARLSON M L, DRISCOLL C L, GIFFORD R H, et al. Cochlear implantation: current and future device options [J]. Otolaryngol Clin North Am, 2012, 45(1): 221-248.

[5] GAO X, TAO Y, LAMAS V, et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents [J]. Nature, 2018, 553(7687): 217-221.

[6] XIONG W, WAGNER T, YAN L, et al. Using injectoporation to deliver genes to mechanosensory hair cells [J]. Nat Protoc, 2014, 9(10): 2438-2449.

[7] HASTIE E, SAMULSKI R J. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success — a personal perspective [J]. Hum Gene Ther, 2015, 26(5): 257-265.

[8] NASO M F, TOMKOWICZ B, PERRY W L, et al. Adeno-associated virus (AAV) as a vector for gene therapy [J]. BioDrugs, 2017, 31(4): 317-334.

[9] ROSE J A, HOGGAN M D, SHATKIN A J. Nucleic acid from an adeno-associated virus: chemical and physical studies [J]. Proc Natl Acad Sci USA, 1966, 56(1): 86-92.

[10] ROSE J A, BERNS K I, HOGGAN M D, et al. Evidence for a single-stranded adenovirus-associated virus genome: formation of a DNA density hybrid on release of viral DNA [J]. Proc Natl Acad Sci USA, 1969, 64(3): 863-869.

[11] SAMULSKI R J, MUZYCZKA N. AAV-Mediated gene therapy for research and therapeutic purposes [J]. Annu Rev Virol, 2014, 1(1): 427-451.

[12] NAUMER M, SONNTAG F, SCHMIDT K, et al. Properties of the adeno-associated virus assembly-activating protein [J]. J Virol, 2012, 86(23): 13038-13048.

[13] EARLEY L F, POWERS J M, ADACHI K, et al. Adeno-associated virus (AAV) assembly-activating protein is not an essential requirement for capsid assembly of AAV serotypes 4, 5, and 11 [J]. J Virol, 2017, 91(3): e01980-16. doi:10.1128/JVI.01980-16.

[14] GAO G, VANDENBERGHE L H, WILSON J M. New recombinant serotypes of AAV vectors [J]. Curr Gene Ther, 2005, 5(3): 285-297.

[15] KEELER A M, FLOTTE T R. Recombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): Where are we, and how did we get here? [J]. Annu Rev Virol, 2019, 6(1): 601-621.

[16] RUSSELL S, BENNETT J, WELLMAN J A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65- mediated inherited retinal dystrophy: a randomised, controlled, openlabel, phase 3 trial [J]. Lancet, 2017, 390(10097): 849-860.

[17] LANDEGGER L D, PAN B, ASKEW C, et al. A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear [J]. Nat Biotechnol, 2017, 35(3): 280-284.

[18] SUZUKI J, HASHIMOTO K, XIAO R, et al. Cochlear gene therapy with ancestral AAV in adult mice: complete transduction of inner hair cells without cochlear dysfunction [J]. Sci Rep, 2017, 7: 45524.

[19] ISGRIG K, MCDOUGALD D S, ZHU J, et al. AAV2.7m8 is a powerful viral vector for inner ear gene therapy [J]. Nat Commun, 2019, 10(1): 427.

[20] WANG D, TAI P W L, GAO G. Adeno-associated virus vector as a platform for gene therapy delivery [J]. Nat Rev Drug Discov, 2019, 18(5): 358-378.

[21] OGDEN P J, KELSIC E D, SINAI S, et al. Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machineguided design [J]. Science, 2019, 366(6469): 1139-1143.

[22] HARTL D, KREBS A R, JÜTTNER J, et al. Cis-regulatory landscapes of four cell types of the retina [J]. Nucleic Acids Res, 2017, 45(20): 11607-11621.

[23] LAN Y, TAO Y, WANG Y, et al. Recent development of AAV-based gene therapies for inner ear disorders [J]. Gene Ther, 2020, 27(7/8): 329-337.

[24] AKIL O, SEAL R P, BURKE K, et al. Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy [J]. Neuron, 2012, 75(2): 283-293.

[25] PAN B, ASKEW C, GALVIN A, et al. Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c [J]. Nat Biotechnol, 2017, 35(3): 264-272.

[26] IIZUKA T, KAMIYA K, GOTOH S, et al. Perinatal Gjb2 gene transfer rescues hearing in a mouse model of hereditary deafness [J]. Hum Mol Genet, 2015, 24(13): 3651-3661.

[27] KIM M A, CHO H J, BAE S H, et al. Methionine sulfoxide reductase B3-targeted in utero gene therapy rescues hearing function in a mouse model of congenital sensorineural hearing loss [J]. Antioxid Redox Signal, 2016, 24(11): 590-602.

[28] CHANG Q, WANG J J, LI Q, et al. Virally mediated Kcnq1 gene replacement therapy in the immature scala media restores hearing in a mouse model of human Jervell and Lange-Nielsen deafness syndrome [J]. Embo Molecular Medicine, 2015, 7(8): 1077-1086.

[29] NIST-LUND C A, PAN B, PATTERSON A, et al. Improved TMC1 gene therapy restores hearing and balance in mice with genetic inner ear disorders [J]. Nat Commun, 2019, 10(1): 236.

[30] SHIBATA S B, RANUM P T, MOTEKI H, et al. RNA interference prevents autosomal-dominant hearing loss [J]. Am J Hum Genet, 2016, 98(6): 1101-1113.

[31] GYORGY B, NIST-LUND C, PAN B, et al. Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss [J]. Nat Med, 2019, 25(7): 1123-1130.

[32] ESTIVILL X, FORTINA P, SURREY S, et al. Connexin-26 mutations in sporadic and inherited sensorineural deafness [J]. Lancet, 1998, 351(9100): 394-398.

AAV介导的听力损失基因治疗进展

Advances in AAV-mediated gene therapy for hearing loss

PDF

可视化

摘要/Abstract

引用本文

使用本文

相关文章 15

编辑推荐

Metrics

本文评价

[1]	向阳建, 邹何, 徐波, 魏云林. 弱毒真菌病毒在植物病害防治中的应用潜力[J]. 自然杂志, 2025, 47(5): 412-418.
[2]	姜利海, 刘培荣, 王志浩, 巫金波. 电驱动智能窗[J]. 自然杂志, 2025, 47(4): 281-288.
[3]	蒋如斌, 刘冬霞, 袁善锋, 张鸿波, 吴学珂. 雷暴电学与人工引雷[J]. 自然杂志, 2025, 47(4): 249-260.
[4]	张文霞, 俞妍, 桂可心, 周天军. 气候变化与野火[J]. 自然杂志, 2025, 47(4): 261-269.
[5]	王云鹤, 李哲涵, 邓书金, 武海斌. 基于光栅芯片的冷原子真空计量[J]. 自然杂志, 2025, 47(4): 289-293.
[6]	付勇搏, 向慧静. 癌症光疗的新纪元：发展、机制和应用[J]. 自然杂志, 2025, 47(3): 190-195.
[7]	冀婧文, 钟俊杰, 钮冰, 陈沁. 图像识别模型在野生动物保护中的应用[J]. 自然杂志, 2025, 47(3): 207-214.
[8]	钱丽嘉, 沈博宇, 郑雨轩, 蒋怿越, 陶鹏杰, 吕东潮. RNA治疗的应用及挑战[J]. 自然杂志, 2025, 47(3): 233-238.
[9]	夏丽丽, 吴陈瑶, 冯炜, 陈雨. 生物催化材料：泛催化精准医疗的“工具箱”[J]. 自然杂志, 2025, 47(3): 183-189.
[10]	赵葛剑, 张新鹏. DeepSeek：从“概率生成”到“因果推理”[J]. 自然杂志, 2025, 47(2): 79-84.
[11]	王邓, 韩健, 郭俊锋, 强亚琴. 寒武纪大爆发期间蜕皮动物躯体构型起源与演化[J]. 自然杂志, 2025, 47(2): 125-133.
[12]	张志飞, 胡亚洲, 梁悦, 刘璠, 罗梅, 张彩彬, 王棹. 寒武纪大爆发组织拼图假说与地球后生动物门类起源[J]. 自然杂志, 2025, 47(2): 95-115.
[13]	郭晓强, 李岩异. RNA研发简史：从微不足道到无比重要[J]. 自然杂志, 2022, 44(6): 480-490.
[14]	赵飞燕, 吴宇轩. 胎儿血红蛋白再生治疗β-血红蛋白病[J]. 自然杂志, 2022, 44(5): 389-397.
[15]	何韫荃, 郭阶雨, 魏香香, 孟丹. 转录因子BACH1的研究进展[J]. 自然杂志, 2022, 44(2): 79-86.